IP Library Granted Patent US 12,377,239
Granted Patent B2
US 12,377,239 · App. 17/593,353 · Granted Aug 5, 2025

Respiratory device for providing bubble CPAP

Inventors: Peter Chi-Yang Hsu (Auckland, NZ); Simei Gomes Wysoski (Auckland, NZ)
Assignee: Fisher & Paykel Healthcare Limited
A61M16/14A61M16/0003A61M16/0051A61M16/0066A61M16/1005A61M16/16A61M16/209A61M2016/0027A61M2205/15A61M2205/3334A61M2205/3365A61M2205/8206
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,239
App. No.
17/593,353
Filed
Sep 16, 2021
Granted
Aug 5, 2025
Kind
B2
Art Unit
3785
USPC
128/203.14
Abstract

Respiratory systems with a flow generator can provide bubble CPAP therapy by controlling the pressure of a flow of gas delivered to a patient. The controller of the respiratory system can control a motor speed of its flow generator so as to control the pressure of the flow of gas. The controller can also detect presence of bubbling and/or possible leaks in the gas pathway of the system. The respiratory system can include a high flow respiratory system.

Claims (35)

1. A respiratory system which is programmed to deliver both a high flow therapy and a bubble CPAP therapy, wherein the respiratory system comprises:

a flow generator;

a humidifier in fluid communication with the flow generator;

an inspiratory conduit in fluid communication with the humidifier; and

a controller configured to control the flow generator to provide the high flow therapy and the bubble CPAP therapy, the controller changeable between the high flow therapy and the bubble CPAP therapy;

wherein the controller is further configured to detect bubbling of a bubbler by monitoring a variation in a flow parameter signal, and wherein in response to the controller detecting bubbling, the controller is configured to output an indication that bubbling is detected or select or switch to the bubble CPAP therapy.

2. The respiratory system of claim 1 , wherein the controller is configured to provide is nasal high flow therapy.

3. The respiratory system of claim 1 , further comprising a non-sealing patient interface coupled to the inspiratory conduit for use when high flow therapy is provided.

4. The respiratory system of claim 3 , wherein the non-sealing patient interface is a nasal cannula.

5. The respiratory system of claim 1 , further comprising:

a sealed patient interface coupled to the inspiratory conduit; and

an expiratory conduit coupled to the sealed patient interface for use when bubble CPAP therapy is provided;

wherein the expiratory conduit is coupled to a pressure regulator to regulate pressure within the sealed patient interface and/or a patient's airways, wherein the pressure regulator comprises a chamber with a column of water, the expiratory conduit being submerged into the column of water at a depth, and wherein the pressure provided to a user is defined or is set by the depth of submersion of the expiratory conduit within the column of water.

6. The respiratory system of claim 1 , further comprising a housing, wherein the flow generator and humidifier are integrated into the housing.

7. The respiratory system of claim 1 , wherein the inspiratory conduit is configured to be used during the high flow therapy and the bubble CPAP therapy.

8. The respiratory system of claim 1 , wherein the controller comprises:

a high flow therapy control program associated with the high flow therapy; and

a bubble CPAP therapy control program associated with the bubble CPAP therapy;

wherein the controller is further configured to:

select and apply the high flow therapy control program when the high flow therapy is selected; and

select and apply the bubble CPAP therapy control program when the bubble CPAP therapy is selected.

9. The respiratory system of claim 8 , wherein the high flow therapy control program and/or the bubble CPAP therapy control program define operating parameters.

10. The respiratory system of claim 9 , wherein the operating parameters comprise at least one of:

one or more motor speed or pressure limits,

one or more alarm conditions,

one or more temperature set points, or

one or more flow limits.

11. The respiratory system of claim 9 , wherein the operating parameters comprises one or more humidity parameters defining a humidity level.

12. The respiratory system of claim 11 , wherein a humidity level to be provided during the high flow therapy is greater than the humidity level to be provided during the bubble CPAP therapy.

13. The respiratory system of claim 1 , wherein the controller is configured to automatically switch therapies when bubbling of the bubbler is detected.

14. The respiratory system of claim 1 , wherein the flow parameter signal comprises a flow signal, a pressure signal, or a combination thereof.

15. The respiratory system of claim 1 , wherein the variation in the flow parameter signal is a variation of a flow parameter signal amplitude from a threshold value or wherein the variation in the flow parameter signal is analyzed in a frequency domain.

16. The respiratory system of claim 1 , wherein the controller providing one of the high flow therapy or the bubble CPAP therapy is a mode selection configured to be selectable by a user.

17. The respiratory system of claim 1 , further comprising a high flow therapy mode kit, wherein the high flow therapy mode kit comprises: a non-sealing patient interface.

18. The respiratory system of claim 1 , further comprising a bubble CPAP therapy mode kit, wherein the bubble CPAP therapy mode kit comprises: a sealing patient interface, an expiratory conduit, and/or a bubbler.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2022
From: WYSOSKI, SIMEI GOMES; HSU, PETER CHI-YANG
To: FISHER & PAYKEL HEALTHCARE LIMITED
Reel/Frame 060240/0501 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2021
From: WYSOSKI, SIMEI GOMES; HSU, PETER CHI-YANG
To: FISHER & PAYKEL HEALTHCARE LIMITED
Reel/Frame 058032/0684 →
Continuity (2)
Provisional Application 62821587 · Mar 21, 2019
Related Publication 20220168536A1 · Jun 2, 2022
References Cited (95)
US 3724454A · Brown · 1973 [cited by applicant]
US 3806102A · Valenta et al. · 1974 [cited by applicant]
US 4192836A · Bartscher et al. · 1980 [cited by applicant]
US 5943473A · Levine · 1999 [cited by applicant]
US 6805120B1 · Jeffrey et al. · 2004 [cited by applicant]
US 7044129B1 · Truschel et al. · 2006 [cited by applicant]
US 7305987B2 · Scholller et al. · 2007 [cited by applicant]
US D657368S · Magee et al. · 2012 [cited by applicant]
US D667838S · Magee et al. · 2012 [cited by applicant]
US 8439031B1 · Rothermel et al. · 2013 [cited by applicant]
US D739427S · Jung et al. · 2015 [cited by applicant]
US D761863S · Debitsch et al. · 2016 [cited by applicant]
US D772252S · Myers et al. · 2016 [cited by applicant]
US D806717S · Bae et al. · 2018 [cited by applicant]
US 10016169B2 · Meador et al. · 2018 [cited by applicant]
US D831059S · Bao · 2018 [cited by applicant]
US D835657S · Anzures et al. · 2018 [cited by applicant]
US D835666S · Saleh et al. · 2018 [cited by applicant]
US D835667S · Saleh et al. · 2018 [cited by applicant]
US 10226200B2 · Vassallo et al. · 2019 [cited by applicant]
US D846583S · Martin et al. · 2019 [cited by applicant]
US 10314990B2 · Richards-Kortum et al. · 2019 [cited by applicant]
US 10342950B2 · Bath et al. · 2019 [cited by applicant]
US D885410S · Butler · 2020 [cited by applicant]
US D887441S · Lorca Norambuena · 2020 [cited by applicant]
US D892141S · Clifford et al. · 2020 [cited by applicant]
US D892142S · Clifford et al. · 2020 [cited by applicant]
US D892832S · Onuma · 2020 [cited by applicant]
US D892833S · Onuma · 2020 [cited by applicant]
US D893547S · Dumas et al. · 2020 [cited by applicant]
US 10864343B2 · Bath et al. · 2020 [cited by applicant]
US D913304S · VanDuyn et al. · 2021 [cited by applicant]
US D914039S · Zimmerman et al. · 2021 [cited by applicant]
US D914726S · Gouliard et al. · 2021 [cited by applicant]
US D916721S · Kirkeby · 2021 [cited by applicant]
US D916743S · Sim et al. · 2021 [cited by applicant]
US D916878S · Kim et al. · 2021 [cited by applicant]
US D918224S · Velamuri et al. · 2021 [cited by applicant]
US D922405S · Norman · 2021 [cited by applicant]
US 11039797B2 · Meador et al. · 2021 [cited by applicant]
US D928190S · Hartman et al. · 2021 [cited by applicant]
US D928813S · Nurutdinov et al. · 2021 [cited by applicant]
US D940729S · Campbell et al. · 2022 [cited by applicant]
US 12048810B2 · Dennis et al. · 2024 [cited by applicant]
US 20030029451A1 · Blair et al. · 2003 [cited by applicant]
US 20030047185A1 · Olsen · 2003 [cited by examiner]
US 20040244804A1 · Olsen et al. · 2004 [cited by applicant]
US 20050150494A1 · DeVries et al. · 2005 [cited by applicant]
US 20060174882A1 · Jagger et al. · 2006 [cited by applicant]
US 20100078024A1 · Andrieux et al. · 2010 [cited by applicant]
US 20110308518A1 · McGroary et al. · 2011 [cited by applicant]
US 20120260718A1 · Sparks et al. · 2012 [cited by applicant]
US 20130228180A1 · Ahmad et al. · 2013 [cited by applicant]
US 20140014110A1 · Adams · 2014 [cited by applicant]
US 20140277914A1 · Fish et al. · 2014 [cited by applicant]
US 20150083123A1 · Tero · 2015 [cited by examiner]
US 20150186023A1 · Alisanski et al. · 2015 [cited by applicant]
US 20150258291A1 · Richards-Kortum · 2015 [cited by examiner]
US 20170224234A1 · Ahlmen · 2017 [cited by examiner]
US 20170304570A1 · Landis · 2017 [cited by examiner]
US 20180015245A1 · Frame et al. · 2018 [cited by applicant]
US 20180071469A1 · Oldfield et al. · 2018 [cited by applicant]
US 20180110948A1 · Dellaca et al. · 2018 [cited by applicant]
US 20180140927A1 · Kito et al. · 2018 [cited by applicant]
US 20190167937A1 · Sims · 2019 [cited by examiner]
US 20190184128A1 · Lucio · 2019 [cited by applicant]
US 20210023318A1 · Tatum · 2021 [cited by examiner]
US 20210181932A1 · Han et al. · 2021 [cited by applicant]
US 20220347423A1 · Babbage et al. · 2022 [cited by applicant]
US 20240024602A1 · Peiris et al. · 2024 [cited by applicant]
EP 777507B1 · 1997 [cited by applicant]
EP 1287843A2 · 2003 [cited by applicant]
EP 2123321A1 · 2009 [cited by applicant]
EP 1061981B1 · 2010 [cited by applicant]
EP 2644220A1 · 2013 [cited by applicant]
WO WO2005063323A1 · 2005 [cited by applicant]
WO WO2010033429A1 · 2010 [cited by applicant]
WO WO2013067580A1 · 2013 [cited by applicant]
WO WO2013148901A1 · 2013 [cited by applicant]
WO WO2013154439A1 · 2013 [cited by applicant]
WO WO2014085431A1 · 2014 [cited by applicant]
WO WO2015165845A1 · 2015 [cited by applicant]
WO WO2016133406A1 · 2016 [cited by applicant]
WO WO2017126980A2 · 2017 [cited by examiner]
WO WO2018033863 · 2018 [cited by applicant]
WO WO2018042355A1 · 2018 [cited by examiner]
WO WO2019193535A1 · 2019 [cited by applicant]
WO WO2019245391A1 · 2019 [cited by applicant]
WO WO2020188526A1 · 2020 [cited by applicant]
WO WO2021046537A1 · 2021 [cited by applicant]
WO WO2021049953A1 · 2021 [cited by applicant]
WO WO2022058982A1 · 2022 [cited by applicant]
International Search Report in corresponding International Patent Application No. PCT/IB/2020/052566, dated Jul. 1, 2020, in 6 pages. [cited by applicant]
Written Opinion in corresponding International Patent Application No. PCT/IB/2020/052566, dated Jul. 1, 2020, in 9 pages. [cited by applicant]
International Preliminary Report on Patentability in corresponding International Patent Application No. PCT/IB/2020/052566, dated Sep. 16, 2021, in 10 pages. [cited by applicant]